-
公开(公告)号:US20120208815A1
公开(公告)日:2012-08-16
申请号:US12449701
申请日:2008-03-03
申请人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Comelia Bellamacina , Kay Huh , Gordana Atallah , Christopher Mcbride , William Antonios-Mccrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
发明人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Comelia Bellamacina , Kay Huh , Gordana Atallah , Christopher Mcbride , William Antonios-Mccrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
IPC分类号: A61K31/5377 , A61K31/4545 , A61P35/00 , C07D413/14 , A61K31/496 , C07D417/14 , A61K31/506 , A61K31/497 , C07D401/14 , C12N5/071
CPC分类号: C07D401/12 , C07D213/78 , C07D239/28
摘要: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物,组合物和方法。 在某些实施方案中,化合物和组合物有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
公开(公告)号:US20140249135A1
公开(公告)日:2014-09-04
申请号:US14273595
申请日:2014-05-09
申请人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Dominguez Garcia
发明人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Dominguez Garcia
IPC分类号: C07D401/12 , A61K31/55 , A61K31/497 , A61K31/4545 , A61K31/444 , C07D491/113 , C07D403/12 , A61K31/506 , C07D241/28 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D497/04 , C07D403/14 , A61K31/553
CPC分类号: C07D401/12 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/55 , A61K31/553 , C07D241/24 , C07D241/28 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D491/113 , C07D497/04
摘要: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物,组合物和方法。 在某些实施方案中,化合物和组合物有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
公开(公告)号:US08822497B2
公开(公告)日:2014-09-02
申请号:US12449701
申请日:2008-03-03
申请人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, Jr. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
发明人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, Jr. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
IPC分类号: A61K31/4545 , C07D401/14
CPC分类号: C07D401/12 , C07D213/78 , C07D239/28
摘要: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物,组合物和方法。 在某些实施方案中,化合物和组合物有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
-